Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Debt (2023 - 2025)

Spyre Therapeutics (SYRE) has disclosed Total Debt for 3 consecutive years, with $22.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 9.01% year-over-year to $22.8 million, compared with a TTM value of $22.8 million through Dec 2025, down 9.01%, and an annual FY2025 reading of $22.8 million, down 9.01% over the prior year.
  • Total Debt was $22.8 million for Q4 2025 at Spyre Therapeutics, up from $11.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $164.4 million in Q2 2023 and bottomed at $1.4 million in Q4 2023.
  • Average Total Debt over 3 years is $33.2 million, with a median of $22.8 million recorded in 2025.
  • The sharpest move saw Total Debt crashed 98.39% in 2024, then surged 2168.94% in 2025.
  • Year by year, Total Debt stood at $1.4 million in 2023, then surged by 1704.32% to $25.1 million in 2024, then decreased by 9.01% to $22.8 million in 2025.
  • Business Quant data shows Total Debt for SYRE at $22.8 million in Q4 2025, $11.0 million in Q3 2025, and $59.9 million in Q2 2025.